Bloomberg Law: Teva’s Orange Book Defeat Sparks Pharma-Patent Strategy Overhaul
June 11, 2025
Member David Gornish is quoted in a Bloomberg Law article regarding the evolving landscape of pharmaceutical patent strategy following a pivotal court ruling involving Teva Pharmaceuticals. The decision, which challenges how patents are listed in the FDA’s Orange Book, is prompting a major shift in how drug-device patents are drafted and defended. David, a former Hatch-Waxman litigator, offered key insights into how this ruling affects patent drafters and the broader implications for the pharmaceutical industry.
Read the full article here.